Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of Relationships between Immune Checkpoint and Methylase Gene Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation.
Takahashi H, Okayama N, Yamaguchi N, Nomura M, Miyahara Y, Mahbub MH, Hase R, Morishima Y, Suehiro Y, Yamasaki T, Tamada K, Takahashi S, Tojo A, Tanabe T. Takahashi H, et al. Among authors: okayama n. Cancers (Basel). 2021 Jun 1;13(11):2752. doi: 10.3390/cancers13112752. Cancers (Basel). 2021. PMID: 34206082 Free PMC article.
Association of interleukin-19 gene polymorphisms with age.
Okayama N, Suehiro Y, Hamanaka Y, Nakamura J, Hinoda Y. Okayama N, et al. J Gerontol A Biol Sci Med Sci. 2007 May;62(5):507-11. doi: 10.1093/gerona/62.5.507. J Gerontol A Biol Sci Med Sci. 2007. PMID: 17522354
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials.
Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Maeda H, et al. Among authors: okayama n. Oncol Lett. 2019 Nov;18(5):4555-4562. doi: 10.3892/ol.2019.10787. Epub 2019 Aug 29. Oncol Lett. 2019. PMID: 31611963 Free PMC article.
TROY is a promising prognostic biomarker in patients with colorectal cancer.
Nishioka M, Suehiro Y, Sakai K, Matsumoto T, Okayama N, Mizuno H, Ueno K, Suzuki N, Hashimoto S, Takami T, Hazama S, Nagano H, Sakaida I, Yamasaki T. Nishioka M, et al. Among authors: okayama n. Oncol Lett. 2018 Apr;15(4):5989-5994. doi: 10.3892/ol.2018.8079. Epub 2018 Feb 16. Oncol Lett. 2018. PMID: 29556315 Free PMC article.
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer.
Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Iwamoto S, et al. Among authors: okayama n. J Cancer. 2018 Oct 18;9(22):4092-4098. doi: 10.7150/jca.26840. eCollection 2018. J Cancer. 2018. PMID: 30519308 Free PMC article.
148 results